N(α)-tert-butoxycarbonyl-N(τ)-tert-butoxycarbonyl-histidine methyl ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N(α)-tert-butoxycarbonyl-N(τ)-tert-butoxycarbonyl-histidine methyl ester
• 英文别名: tert-butyl 4-(2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)-1H-imidazole-1-carboxylate；tert-butyl 4-[3-methoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-oxopropyl]imidazole-1-carboxylate
• 化学式: C₁₇H₂₇N₃O₆
• 分子量: 369.418
• InChiKey: ZYCZFTGHOVFXLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  109
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N(α)-tert-butoxycarbonyl-N(τ)-tert-butoxycarbonyl-histidine methyl ester 在 sodium tetrahydroborate 、 正丁基锂 、 三氟甲烷磺酸甲酯 作用下， 生成 Tert-butyl 4-[3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxobutyl]imidazole-1-carboxylate
  参考文献：
  名称：

  Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method

  摘要：

  本文提供了可与胺基化合物共轭形成稳定共轭物的聚合物α-羟基醛或α-羟基酮试剂，只需一步反应即可完成。在某些实施例中，聚合物试剂本身包含内部质子抽取（碱性）功能基团，以促进更有效的反应。如果必要，通过连接剂适当地定位取代基，以使该基团定位于质子抽取位置，优选提供在α-碳上的氢原子与抽取原子之间提供4或5键间隔。还提供了使用这些试剂的方法以及与生物活性化合物稳定、可溶性共轭物。在优选实施例中，试剂或共轭物的聚合物组分为聚乙二醇。

  公开号：

  US09228053B2
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 L-组氨酸甲酯 在 三乙胺 作用下， 生成 N(α)-tert-butoxycarbonyl-N(τ)-tert-butoxycarbonyl-histidine methyl ester
  参考文献：
  名称：

  Deuterated Angiotensin-Converting Enzyme-2 (ACE-2) Inhibitors

  摘要：

  The present invention is concerned with novel deuterated Angiotensin-Converting Enzyme-2 (ACE-2) inhibitors of general structural formula I, their optically active enantiomers and diastereoisomers, and pharmaceutical salts and compositions thereof, as well as combination therapies which include compounds of the present invention, These compounds have high potency and selectivity for Angiotensin-Converting Enzyme-2 (ACE-2) inhibition, and are useful in the treatment of infectious respiratory diseases including the pandemic disease Covid-19, Severe Acute Respiratory Syndrome (SARS-CoV-2), Severe Acute Respiratory Syndrome (SARS-CoV), and other diseases caused by coronaviruses.

  公开号：

  US20220306646A1

文献信息

• On the allyl protection of the imidazole ring of histidine
  作者：A Malanda Kimbonguila、S Boucida、F Guibé、A Loffet

  DOI：10.1016/s0040-4020(97)00772-2

  日期：1997.9

  The regiospecific synthesis of the N(π)-allyl and the N(τ)-allyl derivatives of N(α)-tert-butoxycarbonyl-histidine is described. The DCC-mediated coupling of N(α)-tert-butoxycarbonyl-N(π)-allyl-(L)-histidine with (L)-prolinamide, used as a test reaction to probe the extent of racemization during coupling processes, was found to occur with good (ca. 97%) conservation of enantiomeric purity. Three methods

  描述了N（α）-叔-丁氧基羰基-组氨酸的N（π）-烯丙基和N（τ）-烯丙基衍生物的区域特异性合成。DCC介导的N（α）-叔丁氧基羰基-N（π）-烯丙基-（L）-组氨酸与（L）-脯氨酰胺的偶联被用作测试反应，以研究偶联过程中外消旋程度。发现具有良好的发生（CA。97％）保留对映体纯度。已经设计了三种方法，所有这些方法均基于催化性钯π-烯丙基化学，用于在温和条件下选择性除去N-咪唑基烯丙基。最后表明，在N（τ）-位的烯丙基可以用作组氨酸的N（π）-取代的衍生物的合成中的临时保护。
• NOVEL SALTS, POLYMORPHS, AND SYNTHETIC PROCESSES REGARDING IMIDAZOLE DERIVATIVE
  申请人：Partridge John Joseph

  公开号：US20110319461A1

  公开（公告）日：2011-12-29

  The present invention relates to a process for producing 2-[1-(S)-carboxy-2(S)-[3-(3,5-dichloro-benzyl)-3H-imidazol-4-yl]-ethylamino]-4-methyl-pentanoic acid, as well as novel salts, including hydrates and solvates thereof, and novel crystalline and amorphous forms thereof.

  本发明涉及一种生产2-[1-(S)-羧基-2(S)-[3-(3,5-二氯苄基)-3H-咪唑-4-基]-乙基氨基]-4-甲基-戊酸的方法，以及其新型盐，包括水合物和溶剂化合物，以及其新型晶体和非晶形式。
• 4,5,6,7-Tetrahydro-1H-imidazo[4,5-c]pyridine derivatives and analogs having antihypertensive activity
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0245637B1

  公开（公告）日：1991-10-16
• BLANKLEY, C. JOHN;HODGES, JOHN C.;KIELY, JOHN S.;KLUTCHKO, SYLVESTER R.
  作者：BLANKLEY, C. JOHN、HODGES, JOHN C.、KIELY, JOHN S.、KLUTCHKO, SYLVESTER R.

  DOI：——

  日期：——
• POLYMERIC ALPHA-HYDROXY ALDEHYDE AND KETONE REAGENTS AND CONJUGATION METHOD
  申请人：Nektar Therapeutics

  公开号：US20170121459A1

  公开（公告）日：2017-05-04

  Provided herein are polymeric α-hydroxy aldehyde or α-hydroxy ketone reagents which can be conjugated to amine-containing compounds to form stable conjugates in a single-step reaction. In selected embodiments, the polymeric reagent itself incorporates an internal proton-abstracting (basic) functional group, to promote more efficient reaction. The substituent is appropriately situated, via a linker if necessary, to position the group for proton abstraction, preferably providing a 4- or 5-bond spacing between the abstracting atom and the hydrogen atom on the α-carbon. Also provided are methods of using the reagents and stable, solubilized conjugates of the reagents with biologically active compounds. In preferred embodiments, the polymeric component of the reagent or conjugate is a polyethylene glycol.